Table 1 Baseline characteristics
Control treatment group (n = 31) | Intensive treatment group (n = 26) | ||
|---|---|---|---|
Gender (M/F) | 24/7 | 22/4 | NS |
Age (yrs) | 58 ± 10 | 60 ± 10 | NS |
Diabetes duration (yrs) | 7 ± 6 | 9 ± 8 | NS |
History of previous CHD | 9 (29 %) | 6 (23 %) | NS |
Tobacco smoking n(%) | 10 (32 %) | 8 (31 %) | NS |
BMI (kg/m2) | 29.9 ± 4.5 | 29.3 ± 4.1 | NS |
Type of ACS n(%): | NS | ||
- Anterior MI | 10 (32.2 %) | 10 (38 %) | |
- Inferior MI | 18 (58.0 %) | 16 (52 %) | |
- Lateral MI | 2 (6.5 %) | 0 (0 %) | |
- Unstable angina | 1 (3.3 %) | 0 (0 %) | |
Heart rate (beats/min) | 66 ± 11 | 63 ± 15 | NS |
Systolic Blood Pressure (mmHg) | 119 ± 18 | 123 ± 17 | NS |
Diastolic Blood Pressure (mmHg) | 74 ± 12 | 76 ± 12 | NS |
Antidiabetic treatment at inclusion n(%): | NS | ||
• metformin | 9 (29 %) | 11 (42 %) | |
• Sulfonylurea or glinide | 11 (35 %) | 15 (58 %) | NS |
• acarbose | 1 (3 %) | 1 (4 %) | NS |
• DPP-4 inhibitor | 1 (3 %) | 2 (8 %) | NS |
• pioglitazone | 0 (0 %) | 2 (8 %) | NS |
• insulin | 17 (55 %) | 15 (58 %) | NS |
Cardiovascular drugs n(%): | |||
• ACE inhibitor/ARB | 28 (90 %) | 24 (92 %) | NS |
• Beta-blocker | 26 (84 %) | 22 (85 %) | NS |
• Antiplatelet agents | 31 (100 %) | 26 (100 %) | NS |
• statin | 29 (94 %) | 25 (96 %) | NS |
Baseline HbA1c (%) | 8.2 ± 1.4 | 8.4 ± 1.2 | NS |
Baseline fructosamine (μmol/l) | 274 ± 45 | 278 ± 52 | NS |
Baseline fasting glucose (mg/dl) | 152 ± 42 | 164 ± 104 | NS |
Baseline VO2 peak (ml/kg/min) | 17.4 ± 4.7 | 16.5 ± 3.8 | NS |
Baseline ventilatory threshold (ml/kg/min) | 12.6 ± 4.0 | 12.2 ± 3.9 | NS |